DexCom (NASDAQ:DXCM) is scheduled to release its earnings data after the market closes on Thursday, February 21st. Analysts expect DexCom to post earnings of $0.14 per share for the quarter.
DXCM opened at $147.90 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. The stock has a market capitalization of $13.19 billion, a price-to-earnings ratio of -255.00 and a beta of 0.84. DexCom has a 12 month low of $53.30 and a 12 month high of $155.85.
Several research firms have commented on DXCM. UBS Group lifted their price target on DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, January 8th. Oppenheimer set a $150.00 price target on DexCom and gave the company a “buy” rating in a report on Thursday, December 6th. Morgan Stanley lowered their price target on DexCom from $150.00 to $135.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Jefferies Financial Group lifted their price target on DexCom to $148.00 and gave the company a “buy” rating in a report on Wednesday, November 7th. Finally, Piper Jaffray Companies boosted their target price on DexCom to $157.00 and gave the stock an “overweight” rating in a report on Wednesday, November 7th. Seven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $143.53.
In other news, EVP Steven Robert Pacelli sold 3,114 shares of the business’s stock in a transaction dated Friday, December 21st. The stock was sold at an average price of $109.41, for a total transaction of $340,702.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Doubleday sold 1,736 shares of the business’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $121.35, for a total value of $210,663.60. Following the sale, the executive vice president now owns 66,804 shares of the company’s stock, valued at approximately $8,106,665.40. The disclosure for this sale can be found here. Insiders have sold a total of 50,457 shares of company stock valued at $6,687,983 in the last quarter. Company insiders own 1.80% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: What is the return on assets formula?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.